Other languages Nevro Corp.

Equities

NVRO

US64157F1030

Market Closed - Nyse Other stock markets 04:00:01 2024-05-24 pm EDT			5-day change	1st Jan Change
9.39 ^USD	0.00%		-17.63%	-56.37%

May. 22	Citigroup Downgrades Nevro to Sell From Neutral, Adjusts Price Target to $9 From $13.50	MT
May. 14	Transcript : Nevro Corp. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nevro Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024	May. 07
Nevro Corp. Announces Resignation of Richard B. Carter as Chief Accounting Officer and Principal Accounting Officer, Effective May 10, 2024	Apr. 25
Nevro 2024 Sales Expected Slightly Below Estimates, RBC Says	Feb. 22
Nevro Corp. Appoints Kirt P. Karros to Board of Directors and Audit Committee of the Board	Feb. 21
Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024	Feb. 21
Nevro Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Jan. 09
Nevro to Cut 5% of Workforce in Restructuring, Says Preliminary Q4 Revenue Rose 2%	Jan. 09
Nevro Acquires Vyrsa Technologies, Closes Term Loan Credit Facility; Shares Rise After Hours	Nov. 30
Nevro Corp. acquired Vyrsa Technologies for $75 million.	Nov. 29
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain	Nov. 20
Nevro Corp. Provides Revenue Guidance for the Fourth Quarter of 2023	Nov. 01
Nevro Corp. Increases Revenue Guidance for the Full-Year 2023	Nov. 01
Nevro Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01
Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy	23-08-16
Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system	23-08-10
Nevro Corp. Revises Earnings Guidance for the Full-Year 2023	23-08-01
Nevro Corp. Provides Revenue Guidance for the Third Quarter of 2023	23-08-01
Nevro Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nevro Corp.

Equities

NVRO

US64157F1030

Other languages

Filters